The G2Solutions project, led by Prof. Dr. Ir. Floris Foijer from the UMCG – ERIBA Research Institute, has received funding from PharmaNL under the PharmaNL Shared Development Infrastructure program for their five-year project. G2Solutions focuses on developing infrastructure for new drug development. “This project demonstrates that we can make unique technologies, such as single-cell sequencing and stem cell and organoid production, available to the world, creating new opportunities for drug development,” says Peter Ketelaar, director of the LIFE Cooperative. The project involves close collaboration between UMCG/ERIBA, UMCG/Genetics, LIFE Cooperative, GenomeScan, and Pivot Park Screening Centre.
Brigitte Drees from Pivot Park Screening Centre: “In this project, we are using our expertise to accelerate and optimize the development of new technologies. With our extensive experience in high-content screening and bioprofiling services, we contribute to identifying promising leads for drug development, which is crucial for the success of this innovative project.”
For more information take a look at the website of PharmaNL.
